FDA approves neladalkib for ALK-positive lung cancer
-
By
-
Teraya Smith
-
November 18, 2026
-
2 min
By
Teraya Smith
November 18, 2026
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
Participants exposed to inaccurate postevent summaries were less likely to correctly remember key details from videos they had previously watched.
September 30, 2026
The FDA approved a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor.
by Teraya Smith
November 10, 2026